Previous 10 | Next 10 |
SPAC Business Combination announcements double compared to the previous week. Potential Deal in the Works Domtar Corporation (UFS) agrees to be acquired by Paper Excellence for $3.02 billion. Chevron Corporation (CVX) closes the acquisition of Noble Midstream Partners (NBLX). ...
Sam Zell's Equity Commonwealth (EQC) wins bidding war for Monmouth Real Estate Investment Corporation (MNR) but arbitrageurs are expecting more. Farm Bureau Property & Casualty Insurance Company bumps up its offer price for FBL Financial Group (FFG) to $61 per share from its previ...
Amryt (AMYT) has agreed to acquire Chiasma (CHMA) in an all-stock transaction following which Amryt shareholders are expected to own ~60% and Chiasma shareholders ~40% of the combined entity.Dual-listed Amryt expects $1B in peak revenue from the deal in addition to ~50M in cost synergies.Per ...
Amryt Pharma (AMYT): Q1 GAAP EPS of -$0.09.Revenue of $48.43M (+8.7% Y/Y)Press Release For further details see: Amryt Pharma reports Q1 results
A mryt R e ports Record Q1 2021 Financial and Operating Results 8. 7 % YoY revenue growth in the quarter to $ 48 . 4 M 16. ...
- Combined business will have three approved commercial products , lomitapide ( Lojuxta ®/ Juxtapid ®), metreleptin ( Myalept ®/ Myalepta ®) , octreotide ( MYCAPSSA ®) and a ro...
Amryt (AMYT) has signed multi-regional distribution agreements with Medison Pharma to distribute Juxtapid (lomitapide) in Canada and Lojuxta (lomitapide) and Myalept (metreleptin) in Israel.Financial details are not disclosed. For further details see: Amryt and Medison Pharma inks distr...
Amryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel DUBLIN, Ireland, and Boston MA, February 4, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developing and commercializ...
Amryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales DUBLIN, Ireland, and Boston MA, January 20, 2021, Amryt (Nasdaq: AMYT, AIM: AMYT), a global, commercial-stage biopharmaceutical company dedicated to acquiring, developin...
The FDA has granted orphan drug designation to Amryt's (AMYT) AP103 for the treatment of Dystrophic Epidermolysis Bullosa ((DEB)), a subset of EB.Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved. AP103 is based o...
News, Short Squeeze, Breakout and More Instantly...
Chiesi Farmaceutici S.p.A. Completes Acquisition of Amryt Pharma Plc Acquisition positions Chiesi to expand patient access to approved treatments and advance efforts to develop new treatments for people living with rare diseases. Parma Italy, Dublin Ireland a...
Turnover at €2 billion 749 million, with growth of 13.6% over 2021 The European market remains at the center, with significant international development The distribution of turnover by therapeutic area is as follows: Air (respiratory diseases) 73%, Rare (rare and ultra-rare disease...
High Court of Justice of England and Wales Sanctions Scheme of Arrangement Acquisition of Amryt Pharma by Chiesi Farmaceutici Expected to Close Mid-April 2023 Dublin, Ireland, April 3 , 2023 Amryt Pharma Plc (“Amryt”) (Nasdaq...